Marketing Gossip : EPZ-6438 Thought As An Absolute Must At This Time

BCR was defined as a serum prostate-specific antigen (PSA) level of ��0.2?ng/mL with a confirmatory value. BCR-free survival (BCRFS), metastasis-free survival (MFS) and cancer-specific survival (CSS) were estimated using the Kaplan�CMeier method and Cox hazards regression models were generated. The mean preoperative PSA level was 6.1?ng/mL, pathological http://www.selleckchem.com/products/PD-0325901.html Gleason grade and stage were ��7 in 68% and ��pT3 in 34% of patients. There was BCR in 470 patients (9.8%), 31 patients developed metastatic disease (0.7%) and 13 patients died from prostate cancer (0.3%) during a mean (range) follow-up of 34.6 (1�C116.7) months. Actuarial 8-year BCRFS, MFS and CSS were 81%, 98.5% and 99.1%, respectively. In patients with node-positive disease, actuarial 5-year BCRFS, MFS, and CSS were 26%, 82%, and 97%. For organ-confined disease, predictors of BCR included pathology Gleason grade (primary Gleason 5 vs 3, hazard ratio [HR] 5.52, P = 0.018; Gleason 4 vs 3, HR 1.97, P = 0.001), preoperative PSA level (10�C20 vs ��10?ng/mL, HR 2.38, P = 0.001), and surgical margin status (positive vs negative, HR 3.84, P http://www.selleck.cn/products/JNJ-26481585.html RARP appears to confer effective long-term biochemical control. To our knowledge, this is the largest report of oncological outcomes in a RARP series to date. ""Study Type �C Therapy (prospective cohort) Level of Evidence?2b To assess whether the response to primary androgen-deprivation therapy (PADT) and radiotherapy (RT) plus adjuvant ADT would be muted in older men, as their tumours might already be relatively androgen insensitive, because serum testosterone levels decline with increasing age. Using the Cancer of the Prostate Strategic Urologic Research Endeavor database, we conducted an observational study evaluating two groups of men treated for prostate cancer from 1995 to 2006. One group of 1748 men was treated with PADT and the second group of 612 men was treated with RT (external beam RT or brachytherapy) with neoadjuvant and/or adjuvant ADT. We tested whether age was a predictor of disease progression in the PADT group and prostate-specific antigen (PSA) recurrence in the RT?+?ADT group (Phoenix definition). Secondary outcomes were all cause (ACM) and prostate cancer-specific mortality (PCSM). In both univariate and multivariate analysis stratifying by clinical risk group, age ( http://www.selleckchem.com/products/epz-6438.html recurrence for the PADT and the RT?+?ADT groups, respectively. Age category had no relationship to increased ACM or PCSM for the RT?+?ADT group. However, for the PADT group the oldest category (>75?years) had an increased hazard ratio (2.26, 95% confidence interval 1.04�C4.88; P?=?0.02) for ACM, but a decreased ratio for PCSM (0.29, 0.21�C0.42; P?